US Stock MarketDetailed Quotes
DRRX Durect
- 1.3000
- 0.00000.00%
Close Oct 15 16:00 ET
- 1.3500
- +0.0500+3.85%
Pre 08:23 ET
40.35MMarket Cap-2131P/E (TTM)
1.3600High1.2800Low13.35KVolume1.3200Open1.3000Pre Close17.48KTurnover0.05%Turnover RatioLossP/E (Static)31.04MShares3.140052wk High8.02P/B38.64MFloat Cap0.470352wk Low--Dividend TTM29.72MShs Float185.0000Historical High--Div YieldTTM6.15%Amplitude0.4703Historical Low1.3080Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Durect Stock Forum
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis
Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design
- Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint;topline results expected within two years of trial initiation
- Protocol for Phase 3 trial builds on data from the AHFIRM Phase 2b tr...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
loading...
loading...
In a significant move within the biopharmaceutical industry, DURECT Corporation (DRRX) has entered into a co-marketing and collaboration agreement with Charles River Laboratories International, Inc. This alliance, announced on March 4, 2024, is set to jointly market and commercialize the ALZET Osmotic Pumps ...
No comment yet